GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

By reclassifying a chemical drug under a different name and label, GlaxoSmithKline avoided rebate obligations tied to the Flovent price inflation, the lawsuit says. "It raised the price so much ...

GSK plc GSK announced that the European Commission ... Sales of the drug are being driven by new patient starts in the United States. Some label expansion studies are ongoing on Jemperli, either ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...

Publicly disclosed details on the GSK agreement are summarized in the image ... I believe that in the future its label will be expanded to additional indications where there is need for an oral ...

Things became litigious in 2017, when a Delaware court found that Teva's label for its generic encouraged doctors to use the drug to treat heart failure in a way that infringed GSK's RE40,000 ...

GSK plc GSK recently announced that EMA has accepted ... In September, the FDA expanded Dupixent’s label in the CRSwNP indication for use in adolescent patients aged 12 to 17 years.

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...